VIP

People run intranasal VIP to dial down inflammation and rebalance an over-active immune system. The headline community use is the chronic inflammatory response syndrome (CIRS / mold-illness) protocol associated with one clinician’s framework, where it’s the last step taken only after everything else is addressed. Outside that, people reach for it for general inflammation and immune balance. Worth knowing up front: VIP is very short-acting, and the strongest real human evidence is in lung conditions (sarcoidosis, pulmonary hypertension) — not the at-home nasal-spray use most people are actually running.

It’s an endogenous peptide — a messenger your body already uses — which is part of its appeal: people frame it as restoring a signal rather than adding a foreign drug. Its anti-inflammatory reach is genuinely broad: in lab and clinical work it pushes the immune system away from inflammatory responses and toward a regulatory, tolerant state. The catch that defines the community conversation is the CIRS protocol: VIP is positioned as the powerful finishing step, but only after you’ve left the water-damaged building and cleared the earlier issues first. That sequencing requirement — and the fact the whole framing comes from essentially one practitioner — is the honest center of this peptide.

VIP binds two G-protein-coupled receptors, VPAC1 and VPAC2, raising intracellular cAMP. Through that it does two distinct things. First, immune modulation: it suppresses inflammatory cytokines from macrophages and dendritic cells, shifts T-cells away from inflammatory Th1 responses toward Th2, and helps generate regulatory T-cells — the controlled human demonstration of this was in sarcoidosis, where inhaled VIP cut macrophage TNF-α and raised regulatory T-cells. Second, vasodilation: it relaxes vascular and airway smooth muscle, which is why it lowers pulmonary artery pressure and why blood pressure is a real consideration. It’s also broken down fast in the body — the short half-life is a genuine limitation, not a footnote.

The defining consideration is vasodilation: VIP can lower blood pressure, and a transient drop after dosing is the effect people are told to watch for — those who run low to begin with are the cautious case. Beyond that, flushing, lightheadedness, headache, and nasal irritation from the spray itself are the commonly mentioned issues, generally described as mild. The honest framing: the real human safety data sits in supervised lung trials (sarcoidosis, pulmonary hypertension, where inhaled doses up to ~300 mcg/day were tolerated), not in casual at-home nasal-spray use, so the community’s comfort rests partly on borrowed reassurance. As always in this space, sourcing is unregulated — insist on a certificate of analysis before running anything.

VIP isn’t run as a free-standing stack ingredient the way the GH or repair peptides are — in its main community use it’s the final element of a long, sequential CIRS protocol, not a peptide you bolt onto others. The “stack” around it is that protocol’s earlier steps (and getting out of the moldy environment), which are treated as prerequisites rather than companions. Outside CIRS it’s mostly run on its own for inflammation/immune balance.